Human Microbiota and Immunotherapy in Breast Cancer - A Review of Recent Developments.

ABSTRACT: Breast cancer (BC) is the most common malignancy and the second cause of cancer-specific death in women from high-income countries. Infectious agents are the third most important risk factor for cancer incidence after tobacco and obesity. Dysbiosis emerged as a key player that may influence cancer development, treatment, and prognosis through diverse biological processes. Metastatic BC has a highly variable clinical course, and more recently, immune checkpoint inhibitors (ICIs) have become an emerging therapy in BC. Even with standardised treatment protocols, patients do not respond similarly, reflecting each individual´s heterogeneity, unique BC features, and tumour microenvironment. However, there is insufficient data regarding predictive factors of response to available treatments for B

SUBMITTER: Vitorino M 

PROVIDER: S-EPMC8832278 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature